# MDS Capital

> MDS Capital is a VC fund in New York backing Biotechnology and Health Care. See 22 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 22
- Last investment: Dec 2024
- Lead investor: 5%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/msd-partners-l-p-/about/
- Website: http://www.mdscapital.com

MDS Capital is a VC fund in New York focused on Biotechnology and Health Care. MDS Capital Corp. was established in 1988 to participate in the financing and development of health-related technologies. Its objective is to become involved with entrepreneurs and scientists who have developed at least the basic concepts and elements of innovative products or services and who require the kinds of financial, managerial and othersupport MDS Capital Corp. is uniquely suited to provide.

## Contacts

5 contacts available for MDS Capital. Shizune tracks 1 team members at MDS Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mds-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 50% |
| Health Care | 9 | 41% |
| Medical | 7 | 32% |
| Medical Device | 6 | 27% |
| Pharmaceutical | 4 | 18% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 23% |
| Series C | 4 | 18% |
| Series D | 3 | 14% |
| Funding Round | 3 | 14% |
| Series A | 2 | 9% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 15 | 68% |
| Canada | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anthony Natale | Vice President | 1 | https://shizune.co/investors/profile/anthony-natale |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NOYACK | NOYACK builds agentic AI technology for wealth management, starting with NOYACK.ai—the first AI agent for financial literacy - and Prophit.ai , the first opensource AI agent for portfolio optimizations of ALL asset classes. The fintech platform uses autonomous AI to deliver personalized financial guidance and construct tax-optimized portfolioscombining traditional accounts (IRAs, 401(k)s, HSAs) with private market investments in venture capital, fine art, and real estate for Millennials and Gen Z investors | $3M | Seed | Dec 03, 2024 |  |
| Spinal Kinetics | Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine.The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic andbiomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms. | $5.3M | Debt Financing | Sep 21, 2009 |  |
| U-Systems | U-Systems designed, developed, manufactured and marketed innovative, ultrasound systems and software to assist the radiologist in detection of breast cancer in women with dense breast tissue. | $16.5M |  | Jun 27, 2007 |  |
| MAKO Surgical | MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specificosteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment.In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal.MAKO Surgical was founded in 2004 and is headquartered in Florida, USA. | $30M | Series C | Feb 06, 2007 |  |
| RenaMed Biologics | RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizesphysiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island. | $40M |  | Sep 07, 2006 |  |
| KAI Pharmaceuticals | KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attackpatients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing. | $35M | Series B | May 02, 2006 |  |
| Resonant Medical | Resonant Medical develops, manufactures, and commercializes 3D ultrasound image-guided adaptive radiotherapy products. Its products include Clarity Breast System, an IGRT solution for precise non-ionizing guidance for boost and conformal breast treatments; Clarity Prostate System, an IGRT solution for precise non-invasive guidance for prostatetreatments; and Multi-Anatomy System, an IGRT solution for precise non-invasive guidance for soft tissue anatomy IGRT treatments, such as gyne and bladder. Resonant Medical serves physicians, physicists, therapists, and administrators. Fred Francis, Anthony Falco, Luc Sirois, and François Perraton founded it in 2000, with its headquarters in Montreal in Canada, and Elekta acquired it as of May 31, 2010. | $24M | Series B | Dec 22, 2005 |  |
| Guava Technologies | Guava Technologies, Inc. develops, designs, and manufactures biotechnology and medical devices. Its products include HIV/AIDS monitoring, viacount cell counting and viability assay, antibody quantification assay, apoptosis assay suite, cell cycle assay, cytotoxicity assay, cell proliferation assay, and benchtop cell analysis systems. GuavaTechnologies also offers flow cytometry systems for cell biology research, drug discovery and development, and HIV/AIDS monitoring. It serves life science research, drug discovery and development, cell biology research, core flow cytometry, and clinical diagnostics markets. The company's products are used in cell counting/viability, antibody quantification, cell cycle and proliferation, cytotoxicity, and apoptosis applications. Guava Technologies, Inc. was founded in 1998 and is headquartered in Hayward, California. As of February 20, 2009, Guava Technologies, Inc. operates as a subsidiary of Millipore Corp. | $7M |  | Nov 29, 2005 |  |
| MAKO Surgical | MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specificosteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment.In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal.MAKO Surgical was founded in 2004 and is headquartered in Florida, USA. | $20M | Series B | Aug 08, 2005 |  |
| Inimex Pharmaceuticals | Inimex Pharmaceuticals, Inc. is a clinical stage company focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body's innate defenses without causing inflammation. | $1.6M | Series A | Dec 08, 2004 |  |

10 of 22 investments shown.

## Co-investors
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 3 deals together
- [Sycamore Ventures](https://shizune.co/investors/profile/sycamore-ventures) — VC Fund, 3 deals together
- [Business Development Bank of Canada](https://shizune.co/investors/profile/business-development-bank-of-canada) — VC Fund, 2 deals together
- [CDIB BioScience Ventures](https://shizune.co/investors/profile/cdib-ventures) — VC Fund, 2 deals together
- [Easton Capital](https://shizune.co/investors/profile/easton-capital) — VC Fund, 2 deals together
- [GrowthWorks Capital](https://shizune.co/investors/profile/growthworks) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does MDS Capital invest in?

MDS Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact MDS Capital?

Public channels for MDS Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at MDS Capital?

The team at MDS Capital includes Anthony Natale (Vice President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co